Welcome to Dor BioPharma: Pioneering Life-Saving Biopharmaceutical Solutions
At Dor BioPharma, we are at the forefront of innovation, dedicated to developing transformative therapies for life-threatening conditions. With expertise in oncology, gastroenterology, and biodefense, we aim to improve patient outcomes and address critical unmet medical needs. Our cutting-edge treatments and groundbreaking research are reshaping healthcare and providing hope to patients worldwide.
Our Mission:
Advancing Healthcare Through Integrity and InnovationDor BioPharma is a late-stage biopharmaceutical company committed to:Developing life-saving treatments for cancer-related complications.Revolutionizing therapies for serious gastrointestinal disorders.Creating biodefense solutions to safeguard public health against bioterrorism threats.We believe in a patient-first approach, combining advanced science with clinical excellence to deliver meaningful results.
Our Lead Product: orBec® (Oral Beclomethasone Dipropionate)
orBec® is a first-of-its-kind oral therapy designed to treat acute gastrointestinal Graft-versus-Host Disease (GI GVHD), a potentially life-threatening complication of allogeneic hematopoietic cell transplantation.
Key Benefits of orBec®:
- Targets GI GVHD locally, reducing the need for systemic immunosuppressive drugs.
- Minimizes side effects while improving treatment outcomes.
- Represents a breakthrough in supportive care for transplant patients.
Learn more about how orBec® is transforming care for GI GVHD patients.
1. Oncology and Supportive Care
We are dedicated to developing innovative therapies that alleviate life-threatening side effects of cancer treatments. From acute GI GVHD to supportive care solutions, our products are designed to improve the quality of life for patients undergoing challenging treatments.
2. Gastrointestinal Disorders
Our research and development efforts target severe gastrointestinal diseases, including:
- Acute GI GVHD
- Pediatric Crohn’s Disease
- Inflammatory Bowel Diseases
By addressing these complex conditions, we aim to enhance patient care and provide solutions where few exist.
3. Biodefense Solutions
In an era of growing global threats, Dor BioPharma is committed to developing vaccines and therapeutics to combat bioterrorism agents. Our focus on biodefense ensures preparedness and protection against emerging health crises.
Our Commitment to Innovation:
Since our inception, Dor BioPharma has been guided by a commitment to excellence and innovation. We combine cutting-edge science with patient-centered care to deliver therapies that make a real difference.Key Achievements:Developed orBec®, a pioneering treatment for GI GVHD.Established a robust pipeline targeting oncology, gastrointestinal diseases, and biodefense.Collaborated with leading researchers and institutions to advance scientific discovery.
October 11, 2011: Formation of a Pediatric Crohn’s Disease Medical Advisory Board to guide future research.
August 12, 2011: Announcement of second-quarter 2011 financial results and key accomplishments.
Partner With Us
Dor BioPharma is actively seeking partnerships to expand its reach and impact. We welcome collaborations in:
- Hematopoietic Stem Cell (HSC) transplantation therapies.
- Supportive care solutions for cancer patients.
- Treatments for gastrointestinal disorders.
- Biodefense and public health preparedness.
Our collaborative approach ensures mutual success and the development of innovative therapies that meet pressing healthcare needs.
Join Us in Transforming HealthcareAt Dor BioPharma, we are driven by the belief that innovation and integrity can change lives. Whether through our cutting-edge therapies, collaborative partnerships, or commitment to excellence, we are reshaping the future of healthcare.
📩 Join Our Newsletter: Stay informed about our latest breakthroughs, research, and events.
📞 Contact Us: Learn more about our products, pipeline, or partnership opportunities.
Together, we can build a healthier, safer future.
Dor BioPharma © 2011. All Rights Reserved.
